Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).

被引：0
|
作者：
Zimmerman, Todd M.
Griffith, Kent A.
Jasielec, Jagoda
Rosenbaum, Cara Ann
McDonnell, Kathryn
Waite-Marin, Jessica
Berdeja, Jesus G.
Raje, Noopur S.
Reece, Donna Ellen
Vij, Ravi
Alonge, Mattina
Rosebeck, Shaun
Gurbuxani, Sandeep
Faham, Malek
Kong, Katherine A.
Levy, Joan
Jakubowiak, Andrzej J.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Northshore Univ Hlth Syst, Evanston, IL USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Washington Univ, Sch Med, St Louis, MO USA
[8] Sequenta Inc, San Francisco, CA USA
[9] Multiple Myeloma Res Consortium, Norwalk, CT USA
[10] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8510
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd
    Raje, Noopur S.
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus G.
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosenbaum, Cara A.
    Jasielec, Jagoda
    Richardson, Paul G.
    Gurbuxani, Sandeep
    Nam, Jennifer
    Severson, Erica
    Wolfe, Brittany D.
    Rosebeck, Shaun
    Stefka, Andrew
    Dytfeld, Dominik
    Griffith, Kent
    Jakubowiak, Andrzej
    BLOOD, 2016, 128 (22)
  • [2] EXTENDED TREATMENT WITH THE COMBINATION OF CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE ( DEX) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Jakubowiak, A.
    Griffith, K.
    Dytfeld, D.
    Vesole, D.
    Jagannath, S.
    Anderson, T.
    Nordgren, B.
    Detweiler-Short, K.
    Lebovic, D.
    Stockerl-Goldstein, K.
    Jobkar, T.
    Wear, S.
    Al-Zoubi, A.
    Ahmed, A.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Hussein, M.
    Yeganegi, H.
    Vij, R.
    HAEMATOLOGICA, 2012, 97 : 115 - 115
  • [3] IMPROVED EFFICACY AFTER INCORPORATING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) INTO KRD TREATMENT WITH CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE (DEX) IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Jakubowiak, A.
    Raje, N.
    Vij, R.
    Reece, D.
    Berdeja, J.
    Vesole, D.
    Jagannath, S.
    Cole, C.
    Faham, M.
    Nam, J.
    Stephens, L.
    Severson, E.
    Revethis, A.
    Wolfe, B.
    Rosebeck, S.
    Gurbuxani, S.
    Rosenbaum, C.
    Jasielec, J.
    Dytfeld, D.
    Griffith, K.
    Zimmerman, T.
    HAEMATOLOGICA, 2016, 101 : 1 - 2
  • [4] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd M.
    Griffith, Kent
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Berdeja, Jesus G.
    Vij, Ravi
    Raje, Noopur
    Reece, Donna E.
    Vesole, David H.
    Jagannath, Sundar
    Kaminski, Mark
    Cole, Craig
    Nam, Jennifer
    Stephens, Leonor A.
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Dytfeld, Dominik
    Jakubowiak, Andrzej J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S40
  • [5] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
    Derman, Benjamin A.
    Cooperrider, Jennifer H.
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD, 2023, 142
  • [6] Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).
    Jakubowiak, Andrzej J.
    Griffith, Kent A.
    Dytfeld, Dominik
    Vesole, David H.
    Jagannath, Sundar
    Anderson, Tara B.
    Nordgren, Brian K.
    Detweiler-Short, Kristen
    Lebovic, Daniel
    Stockerl-Goldstein, Keith
    Jobkar, Terri L.
    Wear, Sandra Marija
    Al-Zoubi, Ammar
    Ahmed, Asra Z.
    Mietzel, Melissa A.
    Couriel, Daniel R.
    Kaminski, Mark Stefan
    Hussein, Mohamad A.
    Yeganegi, Homa
    Vij, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Zimmerman, T. M.
    Griffith, K.
    Jasielec, J. K.
    Rosenbaum, C. A.
    McDonnell, K.
    Marin, J.
    Bakker, J.
    Berdeja, J. G.
    Vij, R.
    Jakubowiak, A. J.
    HAEMATOLOGICA, 2014, 99 : 103 - 103
  • [8] Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
    Jakubowiak, Andrzej J.
    Dytfeld, Dominik
    Jagannath, Sundar
    Vesole, David H.
    Anderson, Tara B.
    Nordgren, Brian K.
    Lebovic, Daniel
    Stockerl-Goldstein, Keith E.
    Griffith, Kent A.
    Hill, Melissa A.
    Harvey, Colleen K.
    Dollard, Akari M.
    Ott, Robert
    Kelley, Susan L.
    Barrickman, Jennifer
    Kauffman, Michael
    Vij, Ravi
    BLOOD, 2010, 116 (21) : 376 - 377
  • [9] Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
    Richardson, Paul G.
    Jacobus, Susanna J.
    Weller, Edie
    Hassoun, Hani
    Lonial, Sagar
    Raje, Noopur S.
    Medvedova, Eva
    McCarthy, Philip L.
    Libby, Edward N.
    Voorhees, Peter M.
    Orlowski, Robert Z.
    Anderson, Larry D., Jr.
    Hurd, David D.
    Pasquini, Marcelo C.
    Masone, Kelly
    Moreau, Philippe
    Avet-Loiseau, Herve
    Attal, Michel
    Anderson, Kenneth Carl
    Munshi, Nikhil C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [10] Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara A.
    Zonder, Jeffrey A.
    Cole, Craig E.
    Chari, Ajai
    Nam, Jennifer
    Stephens, Leonor A.
    McDonnell, Kathryn
    Uribe, Rebecca
    Rosebeck, Shaun
    Rashal, Tami
    Youssoufian, Hagop
    Henry, Sarah
    Shacham, Sharon
    Kauffman, Michael
    Zimmerman, Todd
    Karrison, Theodore
    BLOOD, 2015, 126 (23)
12345